Opportunity ID: 290038

General Information

Document Type: Grants Notice
Funding Opportunity Number: HRSA-17-078
Funding Opportunity Title: Sickle Cell Disease Treatment Demonstration Regional Collaboratives Program
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Health
Category Explanation: https://grants.hrsa.gov/2010/Web2External/Interface/FundingCycle/ExternalView.aspx?fCycleID=c6084989-3725-4b51-b309-206698402829
Expected Number of Awards: 5
Assistance Listings: 93.365 — Sickle Cell Treatment Demonstration Program
Cost Sharing or Matching Requirement: No
Version: Synopsis 2
Posted Date: Nov 10, 2016
Last Updated Date: Jan 13, 2017
Original Closing Date for Applications: Jan 13, 2017
Current Closing Date for Applications: Feb 09, 2017
Archive Date: Feb 27, 2017
Estimated Total Program Funding: $3,575,000
Award Ceiling: $0
Award Floor: $0

Eligibility

Eligible Applicants: Others (see text field entitled “Additional Information on Eligibility” for clarification)
Additional Information on Eligibility: Eligible entities for this cooperative agreement program are any federally-qualified health center, nonprofit hospital or clinic, or university health center that provides primary health care that: (1) has a collaborative agreement with a community-based sickle cell disease organization or a nonprofit entity with experience in working with individuals with sickle cell disease; and (2) demonstrates that it, the collaborative entity, or the experts described in section 712(c)(2)(C) of the American Jobs Creation Act of 2004, has at least five (5) years of experience working with individuals who have sickle cell disease.  Faith-based and community-based organizations that meet these qualifications are eligible to apply.

Foreign entities are not eligible for HRSA awards, unless the authorizing legislation specifically authorizes awards to foreign entities or the award is for research.  This exception does not extend to research training awards or construction of research facilities.

Additional Information

Agency Name: Health Resources and Services Administration
Description: This announcement solicits applications for the Sickle Cell Treatment Demonstration Regional Collaboratives Program.  The purpose of this funding opportunity is to fund Regional Coordinating Centers (RCC) that will establish regional networks and provide leadership and support for regional and statewide activities that will develop and establish systemic mechanisms to improve the prevention and treatment of Sickle Cell Disease, by: (1) increasing the number of providers treating individuals with sickle cell disease using the National Heart, Lung and Blood Institute (NHLBI) Evidence-Based Management of Sickle Cell Disease Expert Panel Report;[1] (2) using telementoring, telemedicine[2] and other provider support strategies to increase the number of providers administering  evidence-based sickle cell care; and 3) developing and implementing strategies to improve access to quality care with emphasis on individual and family engagement/partnership, adolescent transitions to adult life, and care in a medical home.

[1] National Heart, Lung and Blood Institute (NHLBI) Evidence-Based Management of Sickle Cell Disease Expert Panel Report can be found online.  A quick guide of the recommendations can be found at: http://www.nhlbi.nih.gov/sites/www.nhlbi.nih.gov/files/Evd-Bsd_SickleCellDis_Rep2014.pdf 

[2] According to the American Telemedicine Association, telemedicine is the use of medical information exchanged from one site to another via electronic communications to improve a patient’s clinical health status.  Telemedicine includes a growing variety of applications and services using two-way video, email, smart phones, wireless tools and other forms of telecommunications technology.  (http://www.americantelemed.org/main/about/telehealth-faqs- )

Link to Additional Information:
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

Department of Health and Human Services, Health Resources and Services Administration
eivy@hrsa.gov

Email:eivy@hrsa.gov

Version History

Version Modification Description Updated Date
N/A Jan 13, 2017
Jan 13, 2017

DISPLAYING: Synopsis 2

General Information

Document Type: Grants Notice
Funding Opportunity Number: HRSA-17-078
Funding Opportunity Title: Sickle Cell Disease Treatment Demonstration Regional Collaboratives Program
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Health
Category Explanation: https://grants.hrsa.gov/2010/Web2External/Interface/FundingCycle/ExternalView.aspx?fCycleID=c6084989-3725-4b51-b309-206698402829
Expected Number of Awards: 5
Assistance Listings: 93.365 — Sickle Cell Treatment Demonstration Program
Cost Sharing or Matching Requirement: No
Version: Synopsis 2
Posted Date: Nov 10, 2016
Last Updated Date: Jan 13, 2017
Original Closing Date for Applications: Jan 13, 2017
Current Closing Date for Applications: Feb 09, 2017
Archive Date: Feb 27, 2017
Estimated Total Program Funding: $3,575,000
Award Ceiling: $0
Award Floor: $0

Eligibility

Eligible Applicants: Others (see text field entitled “Additional Information on Eligibility” for clarification)
Additional Information on Eligibility: Eligible entities for this cooperative agreement program are any federally-qualified health center, nonprofit hospital or clinic, or university health center that provides primary health care that: (1) has a collaborative agreement with a community-based sickle cell disease organization or a nonprofit entity with experience in working with individuals with sickle cell disease; and (2) demonstrates that it, the collaborative entity, or the experts described in section 712(c)(2)(C) of the American Jobs Creation Act of 2004, has at least five (5) years of experience working with individuals who have sickle cell disease.  Faith-based and community-based organizations that meet these qualifications are eligible to apply.

Foreign entities are not eligible for HRSA awards, unless the authorizing legislation specifically authorizes awards to foreign entities or the award is for research.  This exception does not extend to research training awards or construction of research facilities.

Additional Information

Agency Name: Health Resources and Services Administration
Description: This announcement solicits applications for the Sickle Cell Treatment Demonstration Regional Collaboratives Program.  The purpose of this funding opportunity is to fund Regional Coordinating Centers (RCC) that will establish regional networks and provide leadership and support for regional and statewide activities that will develop and establish systemic mechanisms to improve the prevention and treatment of Sickle Cell Disease, by: (1) increasing the number of providers treating individuals with sickle cell disease using the National Heart, Lung and Blood Institute (NHLBI) Evidence-Based Management of Sickle Cell Disease Expert Panel Report;[1] (2) using telementoring, telemedicine[2] and other provider support strategies to increase the number of providers administering  evidence-based sickle cell care; and 3) developing and implementing strategies to improve access to quality care with emphasis on individual and family engagement/partnership, adolescent transitions to adult life, and care in a medical home.

[1] National Heart, Lung and Blood Institute (NHLBI) Evidence-Based Management of Sickle Cell Disease Expert Panel Report can be found online.  A quick guide of the recommendations can be found at: http://www.nhlbi.nih.gov/sites/www.nhlbi.nih.gov/files/Evd-Bsd_SickleCellDis_Rep2014.pdf 

[2] According to the American Telemedicine Association, telemedicine is the use of medical information exchanged from one site to another via electronic communications to improve a patient’s clinical health status.  Telemedicine includes a growing variety of applications and services using two-way video, email, smart phones, wireless tools and other forms of telecommunications technology.  (http://www.americantelemed.org/main/about/telehealth-faqs- )

Link to Additional Information:
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

Department of Health and Human Services, Health Resources and Services Administration
eivy@hrsa.gov

Email:eivy@hrsa.gov

DISPLAYING: Synopsis 1

General Information

Document Type: Grants Notice
Funding Opportunity Number: HRSA-17-078
Funding Opportunity Title: Sickle Cell Disease Treatment Demonstration Regional Collaboratives Program
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Health
Category Explanation: https://grants.hrsa.gov/2010/Web2External/Interface/FundingCycle/ExternalView.aspx?fCycleID=c6084989-3725-4b51-b309-206698402829
Expected Number of Awards: 5
Assistance Listings: 93.365 — Sickle Cell Treatment Demonstration Program
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Jan 13, 2017
Last Updated Date:
Original Closing Date for Applications:
Current Closing Date for Applications: Jan 13, 2017
Archive Date: Feb 27, 2017
Estimated Total Program Funding: $3,575,000
Award Ceiling: $0
Award Floor: $0

Eligibility

Eligible Applicants: Others (see text field entitled “Additional Information on Eligibility” for clarification)
Additional Information on Eligibility: Eligible entities for this cooperative agreement program are any federally-qualified health center, nonprofit hospital or clinic, or university health center that provides primary health care that: (1) has a collaborative agreement with a community-based sickle cell disease organization or a nonprofit entity with experience in working with individuals with sickle cell disease; and (2) demonstrates that it, the collaborative entity, or the experts described in section 712(c)(2)(C) of the American Jobs Creation Act of 2004, has at least five (5) years of experience working with individuals who have sickle cell disease.  Faith-based and community-based organizations that meet these qualifications are eligible to apply.

Foreign entities are not eligible for HRSA awards, unless the authorizing legislation specifically authorizes awards to foreign entities or the award is for research.  This exception does not extend to research training awards or construction of research facilities.

Additional Information

Agency Name: Health Resources and Services Administration
Description: This announcement solicits applications for the Sickle Cell Treatment Demonstration Regional Collaboratives Program.  The purpose of this funding opportunity is to fund Regional Coordinating Centers (RCC) that will establish regional networks and provide leadership and support for regional and statewide activities that will develop and establish systemic mechanisms to improve the prevention and treatment of Sickle Cell Disease, by: (1) increasing the number of providers treating individuals with sickle cell disease using the National Heart, Lung and Blood Institute (NHLBI) Evidence-Based Management of Sickle Cell Disease Expert Panel Report;[1] (2) using telementoring, telemedicine[2] and other provider support strategies to increase the number of providers administering  evidence-based sickle cell care; and 3) developing and implementing strategies to improve access to quality care with emphasis on individual and family engagement/partnership, adolescent transitions to adult life, and care in a medical home.

[1] National Heart, Lung and Blood Institute (NHLBI) Evidence-Based Management of Sickle Cell Disease Expert Panel Report can be found online.  A quick guide of the recommendations can be found at: http://www.nhlbi.nih.gov/sites/www.nhlbi.nih.gov/files/Evd-Bsd_SickleCellDis_Rep2014.pdf 

[2] According to the American Telemedicine Association, telemedicine is the use of medical information exchanged from one site to another via electronic communications to improve a patient’s clinical health status.  Telemedicine includes a growing variety of applications and services using two-way video, email, smart phones, wireless tools and other forms of telecommunications technology.  (http://www.americantelemed.org/main/about/telehealth-faqs- )

Link to Additional Information:
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

Department of Health and Human Services, Health Resources and Services Administration
eivy@hrsa.gov

Email:eivy@hrsa.gov

Related Documents

Packages

Agency Contact Information: Department of Health and Human Services, Health Resources and Services Administration
eivy@hrsa.gov

Email: eivy@hrsa.gov

Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
93.365 HRSA-17-078 Sickle Cell Disease Treatment Demonstration Regional Collaboratives Program PKG00229174 Feb 09, 2017 View

Package 1

Mandatory forms

290038 SF424_2_1-2.1.pdf

290038 PerformanceSite_2_0-2.0.pdf

290038 Project-1.1.pdf

290038 GG_LobbyingForm-1.1.pdf

290038 Budget-1.1.pdf

290038 SF424B-1.1.pdf

290038 SF424A-1.0.pdf

2025-07-09T09:53:02-05:00

Share This Post, Choose Your Platform!

About the Author: